Madrigal Pharmaceuticals, Inc. Common Stock
MDGL
$513.43
+0.11%
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. The company is a first-mover and potential market leader in the MASH space, with its lead asset, Rezdiffra (resmetirom), being the first and only FDA-approved therapy for the condition. The current investor narrative is dominated by the commercial launch trajectory of Rezdiffra, with debates centered on the pace of revenue ramp, market penetration, and the company's ability to transition from a cash-burning R&D entity to a profitable commercial enterprise, as evidenced by its recent quarterly revenue generation.…
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
$513.43
Related headlines
Investment Opinion: Should I buy MDGL Today?
Rating: Hold. The core thesis is that Madrigal is a compelling story with proven commercial traction, but its premium valuation fully reflects this success and leaves little margin for error, warranting a cautious stance until the path to profitability becomes clearer.
Supporting this Hold rating are several key data points. First, the valuation is rich at a trailing PS of 13.63x (EV/Sales of 9.79x forward), a premium to the biotech sector. Second, while revenue growth is exceptional at 211% YoY in Q4 2025, the stock's 6-month price change of -14.43% suggests the market is already questioning the sustainability of this pace. Third, profitability metrics remain deeply negative (operating margin: -31.3%), and fourth, the implied upside is unclear due to insufficient consensus price targets, though analyst sentiment remains bullish.
The rating would upgrade to a Buy if the forward EV/Sales multiple compresses below 7x on sustained revenue growth, or if the company demonstrates a clear quarterly path to positive operating income. It would downgrade to a Sell if quarterly revenue growth decelerates below 50% YoY, or if the cash burn rate increases sequentially. Relative to its own history (PS has collapsed from >400x) and the sector, the stock is fairly valued to slightly overvalued, pricing in near-perfect execution.
Sign up to view all
MDGL 12-Month Price Forecast
Madrigal is a classic high-risk, high-reward biotech transition story. The commercial launch of Rezdiffra is undeniably successful, providing a strong foundation. However, the stock's recent weakness and premium valuation suggest the market is looking past initial sales to the challenges of sustaining growth and achieving profitability. The neutral stance reflects this balance: the opportunity is large, but the price of admission is high. The stance would turn bullish on evidence of sustained operating margin improvement or valuation compression on continued growth. It would turn bearish on any material deceleration in quarterly revenue growth or a significant increase in cash burn.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Madrigal Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $667.46 and implied upside of +30.0% versus the current price.
Average Target
$667.46
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$411 - $667
Analyst target range
Insufficient analyst coverage data is available to provide a detailed consensus view; the provided data includes estimated financials but lacks explicit analyst count, recommendation distribution, and price targets. This limited coverage is typical for a commercial-stage biotech that has recently transitioned from a development-focused story, and it can lead to higher stock price volatility and less efficient price discovery as the investment community builds its models. The available institutional ratings show a pattern of reiterated 'Buy' or 'Overweight' ratings from firms like HC Wainwright, Oppenheimer, and Truist Securities in late 2025, indicating maintained bullish sentiment among covering analysts following the drug's launch and early financial results.
Bulls vs Bears: MDGL Investment Factors
The bull case for Madrigal is compelling, anchored by its first-mover status in a multi-billion dollar MASH market and a demonstrated, explosive revenue ramp that validates strong initial demand. However, the bear case presents substantial risks, primarily centered on a premium valuation that prices in flawless execution while the company remains deeply unprofitable and cash-burning. Currently, the bull side has stronger evidence due to the concrete, accelerating revenue figures and the scarcity value of an approved MASH therapy. The single most important tension in the investment debate is the race between revenue scalability and cash burn. If revenue growth continues to accelerate and operating leverage kicks in swiftly, the stock could re-rate higher. If growth plateaus or expenses remain elevated, the premium multiple will collapse, leading to significant downside.
Bullish
- First-Mover in Large MASH Market: Rezdiffra is the first and only FDA-approved therapy for MASH, a serious liver disease with high unmet need. This grants Madrigal a significant competitive moat and pricing power, as evidenced by the rapid revenue ramp from $0 in Q1 2024 to $321.1 million in Q4 2025, representing 211% YoY growth in that quarter.
- Exceptional Revenue Growth Trajectory: Commercial launch execution has been strong, with sequential quarterly revenue accelerating from $137.3M (Q1 2025) to $321.1M (Q4 2025). This validates the market opportunity and suggests robust initial physician adoption and patient demand for the therapy.
- High Gross Margins and Improving Losses: The company boasts pharmaceutical-grade gross margins of 94.1%. Furthermore, the net loss improved significantly from -$114.2 million in Q3 2025 to -$58.6 million in Q4 2025, indicating operating leverage is beginning to materialize as revenue scales.
- Strong Institutional & Analyst Sentiment: Despite limited coverage, available institutional ratings from late 2025 show reiterated 'Buy' or 'Overweight' ratings from firms like HC Wainwright and Oppenheimer. This maintained bullish sentiment post-launch signals confidence in the commercial story.
Bearish
- Premium Valuation Despite Heavy Losses: The stock trades at a trailing PS ratio of 13.63x, a premium to typical biotech averages, while the company remains deeply unprofitable with a net margin of -30.1% and negative ROE of -47.8%. This creates vulnerability to multiple compression if growth decelerates.
- Sustained Cash Burn and Negative FCF: Madrigal is burning significant cash, with trailing twelve-month free cash flow of -$190.0 million. The path to positive cash flow is critical, as continued losses could necessitate future capital raises, diluting shareholders.
- Single-Asset, Single-Market Dependence: The entire investment thesis hinges on the commercial success of Rezdiffra for MASH. Any setback in market penetration, payer reimbursement, safety profile, or competitive entry poses an existential risk to the company's valuation.
- Technical Downtrend and High Volatility: The stock is down -14.43% over the past 6 months and has retreated from its 52-week high of $615 to ~$506, indicating stalled momentum. Its beta of -1.059 signals extreme, idiosyncratic volatility that is inversely correlated with the market, adding significant risk.
MDGL Technical Analysis
The stock is in a pronounced downtrend from its 52-week highs, with a 1-year price change of +78.89% but a 6-month change of -14.43%, indicating a significant recent pullback. As of the latest close of $505.75, the stock is trading at approximately 82% of its 52-week range ($276.67 to $615.00), positioning it closer to the high end but having retreated substantially from the peak, suggesting momentum has stalled after a strong prior run. Recent momentum is weak and diverging from the longer-term uptrend, with the stock down -1.19% over the past month and up 14.64% over the past three months, underperforming the SPY's gains of +0.74% and +15.14% over the same periods, respectively, indicating relative weakness. Key technical support is at the 52-week low of $276.67, with resistance at the 52-week high of $615.00; a sustained break below the recent lows near $432 could signal a deeper correction, while a reclaim of the $600 level would be needed to restore the bullish thesis. The stock's beta of -1.059 suggests it has exhibited an inverse, highly volatile relationship with the broader market recently, which is atypical and adds significant idiosyncratic risk for investors.
Beta
-1.06
-1.06x market volatility
Max Drawdown
-29.4%
Largest decline past year
52-Week Range
$278-$615
Price range past year
Annual Return
+81.4%
Cumulative gain past year
| Period | MDGL Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | -1.6% |
| 3m | +11.1% | +11.7% |
| 6m | -14.8% | +6.3% |
| 1y | +81.4% | +22.2% |
| ytd | -13.5% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDGL Fundamental Analysis
Revenue trajectory has transformed dramatically with the launch of Rezdiffra, growing from $0 in Q1 2024 to $321.1 million in Q4 2025, representing a year-over-year growth rate of 211% for that quarter. The multi-quarter trend shows accelerating commercialization, with sequential revenue increasing from $137.3 million in Q1 2025 to $321.1 million in Q4 2025, indicating strong initial uptake and validating the significant market opportunity in MASH. The company remains deeply unprofitable on a net income basis, reporting a net loss of $58.6 million in Q4 2025, though this represents a significant improvement from a net loss of $114.2 million in Q3 2025. Gross margins are exceptionally high at 94.1%, typical for a pharmaceutical company, but operating margins were deeply negative at -31.3% in the last quarter, reflecting substantial commercial and R&D investments that currently outpace revenue. The balance sheet shows a current ratio of 4.01, indicating strong short-term liquidity, but the company is burning cash with a trailing twelve-month free cash flow of -$190.0 million. The debt-to-equity ratio of 0.59 suggests a moderate level of leverage, while the negative Return on Equity of -47.8% and negative Return on Assets of -17.6% underscore the company's pre-profitability stage, with financial health dependent on its ability to convert high revenue growth into positive cash flow.
Quarterly Revenue
$321083000.0B
2025-12
Revenue YoY Growth
+2.10%
YoY Comparison
Gross Margin
+0.92%
Latest Quarter
Free Cash Flow
$-190020000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDGL Overvalued?
Given the company's negative net income and negative EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 13.63x, while the forward-looking metric, EV/Sales, is 9.79x, with the lower forward multiple implying the market expects significant revenue growth to continue. Compared to typical biotechnology industry averages, a PS ratio of 13.6x is at a premium, reflecting the market's pricing of Madrigal's first-mover advantage in a large, untapped market and its rapid revenue ramp from a near-zero base. Historically, the stock's own PS ratio has compressed significantly from levels above 400x in mid-2024 (when revenue was minimal) to the current 13.6x, indicating the valuation has normalized as sales have materialized; the current multiple sits well below its extreme historical highs but is still pricing in substantial future growth, leaving it vulnerable to any commercial execution missteps.
PE
-45.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -56x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-50.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. Madrigal's financial health is entirely dependent on converting its high revenue growth into profitability, a transition that is not guaranteed. The company reported a net loss of $58.6 million in its latest quarter and has a trailing FCF burn of -$190 million. With a debt-to-equity of 0.59, leverage is moderate, but the negative ROE of -47.8% underscores the pre-profitability stage. The core risk is revenue concentration; 100% of sales are from Rezdiffra, making the company vulnerable to any single commercial, clinical, or regulatory setback in the MASH market.
Market & Competitive Risks are significant. The stock trades at a premium PS ratio of 13.6x, which is vulnerable to compression if revenue growth decelerates from its current triple-digit pace or if sector sentiment sours on pre-profitability biotechs. The atypical beta of -1.059 indicates the stock trades on highly volatile, company-specific news rather than market fundamentals, amplifying downside moves on any negative development. While it is the first mover, the large MASH market will inevitably attract competition, and the success of later-stage pipeline candidates from rivals poses a long-term threat to market share and pricing power.
Worst-Case Scenario involves a combination of slower-than-expected prescription growth, heightened payer pushback on Rezdiffra's price, and the emergence of compelling clinical data for a competitor's therapy. This could trigger a downward spiral of analyst downgrades, multiple compression from the current PS of 13.6x towards the single digits, and a failure to achieve operating leverage. The realistic downside could see the stock retesting its 52-week low of $276.67, which represents a potential loss of approximately -45% from the current price near $506. The recent max drawdown of -29.36% from the 52-week high provides a recent precedent for severe volatility.
FAQ
The key risks are: 1) Commercial/Execution Risk: The entire company depends on one drug, Rezdiffra. Slower-than-expected market penetration or payer access issues could crater revenue growth. 2) Financial Risk: The company is burning cash at a rate of -$190M TTM and remains unprofitable (net margin: -30.1%), risking future dilution. 3) Valuation Risk: The premium PS ratio of 13.6x is vulnerable to severe compression if growth decelerates. 4) Competitive Risk: As the first mover, it faces inevitable competition from other late-stage MASH therapies, which could erode long-term market share and pricing power. The atypical beta of -1.059 also indicates extreme stock-specific volatility.
The 12-month forecast is bifurcated, with a high degree of uncertainty. Our analysis outlines three scenarios: a Bull Case (30% probability) targeting $600-$650 driven by sustained hyper-growth and operating leverage; a Base Case (50% probability) targeting $480-$550 assuming successful but moderating growth; and a Bear Case (20% probability) targeting $300-$400 if commercial execution stumbles. The Base Case is most likely, predicated on the assumption that revenue growth continues but decelerates from its initial explosive pace as the launch matures, with the valuation multiple stabilizing. The key variable is the quarterly revenue trajectory over the next few reports.
MDGL appears fairly valued to slightly overvalued based on current metrics. The primary valuation metric, the Price-to-Sales ratio, stands at 13.63x trailing and 9.79x forward (EV/Sales). This is at a premium to the broader biotech industry, reflecting its first-mover advantage and explosive growth. However, this premium is juxtaposed against deeply negative profitability (ROE: -47.8%). The valuation implies the market expects near-flawless commercial execution and a rapid transition to profitability. Compared to its own history, the multiple has normalized dramatically from >400x when sales were negligible. In summary, the market is paying a full price for future success that is not yet guaranteed.
MDGL is a high-risk, high-potential reward investment that may be suitable for a specific investor profile. For aggressive growth investors comfortable with biotech volatility and a multi-year horizon, the stock offers a direct play on a validated, large market opportunity. The 211% YoY revenue growth is compelling. However, at a premium PS ratio of 13.6x and with the company still burning significant cash (-$190M FCF), the stock is fully valued and leaves little room for error. It is not a good buy for conservative or income-seeking investors. A good entry would be on a pullback that reduces the valuation multiple or after clearer evidence of a path to profitability emerges.
MDGL is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. The company is in the early stages of a commercial launch that will take years to fully play out across the global MASH market. The stock exhibits high idiosyncratic volatility (beta: -1.059) and pays no dividend, making it unsuitable for short-term trading or income portfolios. Long-term investors are betting on the company's ability to capture significant market share and eventually translate revenue into sustained profits. Short-term price movements are likely to be driven by quarterly revenue beats/misses and clinical news, which are difficult to predict consistently.